Vimta Labs Limited, India’s leading Contract Research and Testing Organisation, has announced its financial results for the quarter and half year ended September 30, 2024.

Key Result Highlights for the Q2 & H1 FY25 (Consolidated):

Q2 FY25

* Total Income for Q2 FY25 was at Rs. 85.4 crore

* EBITDA for Q2 FY25 was Rs. 30.6 crore; EBITDA margin was at 35.8%

* Q2 FY25 PAT was at Rs. 17 crore; PAT margin was at 19.9%

H1 FY25

* Total Income for H1 FY25 was at Rs. 161 crore

* EBITDA for H1 FY25 was Rs. 57.2 crore; EBITDA margin was at 35.5%

* H1 FY25 PAT was at Rs. 30.9 crore; PAT margin was at 19.2% 

Commenting on results, Harita Vasireddi, Managing Director, Vimta Labs Limited, said: "We are pleased to report a strong operational performance for Q2FY25, with revenues of ₹854 mn, reflecting a 26.4% YoY growth. Our EBITDA rose by 57.3% YoY, and net profit surged by 109.9%. This performance was primarily driven by our pharmaceutical services, which continue to lead the business.

As stated in our August 30, 2024, press release, Vimta Labs has divested the Diagnostic and Pathological services business to Thyrocare Technologies. This decision allows us to sharpen our focus on core services and optimize resources for sustained growth, resulting in a significant improvement in our EBITDA margins, which now exceed 35%, up from the previous range of 23% to 30%.

Looking ahead, our Pharmaceutical services continue to show promising growth, and we anticipate that our food testing services will also contribute to growth in coming quarters. We are also expanding our electrical and electronics testing capabilities and preparing to commission a new facility in couple of quarters. We remain committed to driving sustainable and impactful growth for our investors.”